SynCo Bio Partners Completes Manufacture and Release of Actogenix’ Lead Product for Phase II Clinical Trials

News   May 16, 2008

 
SynCo Bio Partners Completes Manufacture and Release of Actogenix’ Lead Product for Phase II Clinical Trials
 
 
 

RELATED ARTICLES

The Resilience of the Down's Syndrome Genome

News

People with Down's Syndrome have a genome optimised against rare mutation and a well-balanced gene expression rate, a study suggests.

READ MORE

CRISPR Technology Used to Make Stem Cells

News

In a world first, CRISPR genome editing has been used to reprogram skin cells to function as pluripotent stem cells.

READ MORE

Magnetic MicroRNAs Could Help Treat Incontinence

News

An unlikely combination of magnets and MicroRNAs might be a novel treatment for constipation and incontinence patients.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE